Role and mechanism of action of sclerostin in bone
- PMID: 27742498
- PMCID: PMC5328835
- DOI: 10.1016/j.bone.2016.10.007
Role and mechanism of action of sclerostin in bone
Abstract
After discovering that lack of Sost/sclerostin expression is the cause of the high bone mass human syndromes Van Buchem disease and sclerosteosis, extensive animal experimentation and clinical studies demonstrated that sclerostin plays a critical role in bone homeostasis and that its deficiency or pharmacological neutralization increases bone formation. Dysregulation of sclerostin expression also underlies the pathophysiology of skeletal disorders characterized by loss of bone mass, as well as the damaging effects of some cancers in bone. Thus, sclerostin has quickly become a promising molecular target for the treatment of osteoporosis and other skeletal diseases, and beneficial skeletal outcomes are observed in animal studies and clinical trials using neutralizing antibodies against sclerostin. However, the anabolic effect of blocking sclerostin decreases with time, bone mass accrual is also accompanied by anti-catabolic effects, and there is bone loss over time after therapy discontinuation. Further, the cellular source of sclerostin in the bone/bone marrow microenvironment under physiological and pathological conditions, the pathways that regulate sclerostin expression and the mechanisms by which sclerostin modulates the activity of osteocytes, osteoblasts, and osteoclasts remain unclear. In this review, we highlight the current knowledge on the regulation of Sost/sclerotin expression and its mechanism(s) of action, discuss novel observations regarding its role in signaling pathways activated by hormones and mechanical stimuli in bone, and propose future research needed to understand the full potential of therapeutic interventions that modulate Sost/sclerostin expression.
Keywords: Anabolism; Bone formation; Bone resorption; Glucocorticoids; Multiple myeloma; Osteocytes; PTH; Wnt/βcatenin signaling.
Copyright © 2016 Elsevier Inc. All rights reserved.
Conflict of interest statement
Authors have no conflicts of interest to report.
Figures
Similar articles
-
Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.JCI Insight. 2018 Jun 7;3(11):e98673. doi: 10.1172/jci.insight.98673. eCollection 2018 Jun 7. JCI Insight. 2018. PMID: 29875318 Free PMC article.
-
Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.J Biol Chem. 2013 Oct 11;288(41):29809-20. doi: 10.1074/jbc.M113.485938. Epub 2013 Aug 20. J Biol Chem. 2013. PMID: 23963454 Free PMC article.
-
Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action.Eur J Pharmacol. 2018 May 5;826:39-47. doi: 10.1016/j.ejphar.2018.02.028. Epub 2018 Feb 22. Eur J Pharmacol. 2018. PMID: 29476877 Review.
-
Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone.J Mol Histol. 2007 Aug;38(4):261-9. doi: 10.1007/s10735-007-9096-3. Epub 2007 Jun 5. J Mol Histol. 2007. PMID: 17549589
-
Does osteocytic SOST suppression mediate PTH bone anabolism?Trends Endocrinol Metab. 2010 Apr;21(4):237-44. doi: 10.1016/j.tem.2009.12.002. Epub 2010 Jan 13. Trends Endocrinol Metab. 2010. PMID: 20074973 Review.
Cited by
-
Oral and Gingival Crevicular Fluid Biomarkers for Jawbone Turnover Diseases: A Scoping Review.Diagnostics (Basel). 2024 Sep 30;14(19):2184. doi: 10.3390/diagnostics14192184. Diagnostics (Basel). 2024. PMID: 39410587 Free PMC article. Review.
-
Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality.Diabetol Metab Syndr. 2024 Sep 6;16(1):217. doi: 10.1186/s13098-024-01440-7. Diabetol Metab Syndr. 2024. PMID: 39238022 Free PMC article. Review.
-
Sclerostin antibody corrects periodontal disease in type 2 diabetic mice.JCI Insight. 2024 Jul 18;9(16):e181940. doi: 10.1172/jci.insight.181940. JCI Insight. 2024. PMID: 39171525 Free PMC article.
-
Induction of osteoblast apoptosis stimulates macrophage efferocytosis and paradoxical bone formation.Bone Res. 2024 Aug 5;12(1):43. doi: 10.1038/s41413-024-00341-9. Bone Res. 2024. PMID: 39103355 Free PMC article.
-
PTH receptor signalling, osteocytes and bone disease induced by diabetes mellitus.Nat Rev Endocrinol. 2024 Nov;20(11):661-672. doi: 10.1038/s41574-024-01014-7. Epub 2024 Jul 17. Nat Rev Endocrinol. 2024. PMID: 39020007 Review.
References
-
- Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179–192. - PubMed
-
- Poole KE, Van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19(13):1842–1844. - PubMed
-
- Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280(20):19883–19887. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
